institutionsInstitution
LYSA – The Lymphoma Study Association
aka LYSA, GELA, Groupe d'Etude des Lymphomes de l'Adulte, GOELAMS, LYSARC
The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.
LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.
Location
Pierre-Bénite (Lyon), FR
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#210 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
- LNH-98.5 (R-CHOP)
- PRIMA (rituximab maintenance)
- POLARIX (with Roche)
- REALYSA cohort and Lymphopath